Orbimed Advisors LLC Oncocyte Corp Transaction History

Orbimed Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.76 - $15.98 $725,824 - $15.3 Million	-955,032 Reduced 33.65%	1,882,768 $1.37 Million
Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $564,160 - $1 Million	-656,000 Reduced 18.78%	2,837,800 $2.55 Million
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $1.3 Million - $2.29 Million	637,800 Added 22.33%	3,493,800 $7.58 Million
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $2.67 Million - $4.45 Million	756,000 Added 36.0%	2,856,000 $10.2 Million
Q1 2021 May 17, 2021	BUY	$2.39 - $6.5 $5.02 Million - $13.7 Million	2,100,000 New	2,100,000 $10.9 Million

411K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $294M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.